AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 261 min read$EVGN

Tarcic Gabi purchased $677 of EVGN

Tarcic Gabi (Chief Development Officer) purchased 1,129 shares of Evogene Ltd. (EVGN) at $0.60 on 2026-06-04.

Original reporting
SEC EDGAR · Tarcic Gabi
Published Aug 26, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EVGN
Neutral
high confidence
Mentioned
$EVGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EVGNNeutralLow
01

Why it matters

The purchase is modest and unlikely to move the stock, but it adds a data point for monitoring insider sentiment.

02

Market read

Minor insider purchase with limited trading relevance.

03

What to watch

Potential upcoming product milestones not disclosed may motivate the purchase.

Relevance 4/10Novelty 4/10Timing: filed Aug 26 2026

Background

Form 4 filings disclose insider trades; this is the first public report of this purchase.

Company-level read

Ticker impact

$EVGNNeutralHigh confidence
Context

Chief Development Officer bought 1,129 shares at $0.60 each, total $677, filing a Form 4 on Aug 26 2026.

Expected impact

Minimal short‑term impact; likely negligible price movement.

Evidence & confidence

The transaction size is tiny relative to market cap and typical daily volume, so market reaction is expected to be limited.

Market effects

Sector

No material effect on biotech sector; typical insider activity.

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buying could be a subtle bullish sign despite small size.

Key entities

  • Company
    Evogene Ltd.

    Biotech firm listed on NASDAQ (EVGN).

  • Insider
    Tarcic Gabi

    Chief Development Officer of Evogene.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EVGN insider trading history →

Related articles

AUG 18
$EVGNMed

Evogene Ltd. (EVGN): Financial results for Q2 2026

Evogene Ltd. (EVGN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Evogene Reports Second Quarter and First Half 2026 Financial Results · Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product d

SEC EDGAR 6-K2 min